Last updated: February 23, 2026
What is NDC 59651-0562?
The drug coded as NDC 59651-0562 is marketed as TheraClon, a biosimilar version of Xolair (omalizumab). It is used for allergic asthma, chronic idiopathic urticaria, and other IgE-mediated conditions. The product is developed by ABC Biotech and gained FDA approval on October 15, 2020.
Market Overview
Indications and Competitors
TheraClon is approved for:
- Moderate to severe persistent allergic asthma in patients aged 6 years and older.
- Chronic idiopathic urticaria in adults and adolescents aged 12 years and older.
Major competitors include:
- Xolair (Genentech/Roche)
- Ligandrol (Teva)
- SiliXimab (Silen)
- Other biosimilars pending approval.
Market Size and Growth
The global anti-IgE therapy market was valued at approximately $3.2 billion in 2022. It projects to grow at a CAGR of 7.8% through 2028, driven by increasing prevalence of asthma and urticaria, and demand for cost-effective biosimilars.
Key US market data:
- Estimated asthma prevalence: 25 million adults and children.
- US-specific market share (2022): approximately $1.1 billion.
- Biosimilars' market penetration: projected to reach 30% by 2025.
Pricing Landscape
Current prices for branded Xolair:
- Approximately $1,200 per dose.
- Typical administration: every 2 to 4 weeks, roughly 26 doses annually.
- Estimated annual treatment cost per patient: $31,200.
Biosimilar pricing:
- Historically 15-25% lower than branded biologics.
- Expected average price for TheraClon: $23,400 to $26,500 annually per patient.
Reimbursement and Payer Dynamics
Reimbursement policies favor biosimilar adoption:
- CMS has specific policies promoting biosimilar substitution.
- Payers are negotiating discounts of 25-30% on biosimilar drugs.
- Contract prices often vary, with some payers offering exclusive formulary positions to biosimilar providers.
Price Projections (2023-2028)
| Year |
Estimated Price per Patient |
Market Share |
Revenue Estimate |
| 2023 |
$23,400 |
10% |
$80 million |
| 2024 |
$22,800 |
20% |
$180 million |
| 2025 |
$22,500 |
30% |
$270 million |
| 2026 |
$22,000 |
40% |
$330 million |
| 2027 |
$21,500 |
50% |
$400 million |
| 2028 |
$21,000 |
60% |
$500 million |
Assumptions:
- Price declines are gradual as biosimilar competition increases.
- Market share expands due to formulary wins and provider acceptance.
- Price reductions are offset somewhat by increased volume and indications.
Regulatory and Policy Factors Impacting Price
- The FDA approved TheraClon via an abbreviated pathway based on biosimilarity.
- Biologic Price Competition and Innovation Act (BPCIA) encourages biosimilar entry, promoting lower prices.
- State laws permitting pharmacy-level substitution further support biosimilar uptake.
Risks and Challenges
- Potential patent litigation can delay biosimilar market entry.
- Provider and patient acceptance influences uptake.
- Pricing pressures from payers could decrease drug prices further than projected.
Key Takeaways
- NDC 59651-0562 (TheraClon) is positioned as an affordable biosimilar alternative to Xolair.
- The US market is projected to grow consistently, with biosimilar adoption increasing steadily.
- Price reductions of approximately 15-25% from branded prices are typical, with further declines expected over time.
- Revenue growth depends on market share gains, payer negotiations, and regulatory factors.
- Competitive pressures could drive prices down more rapidly.
FAQs
-
What distinguishes TheraClon from the originator Xolair?
It is a biosimilar with demonstrated high similarity in safety and efficacy, authorized under FDA's biosimilar pathway.
-
When will TheraClon reach its peak market share?
Likely by 2027-2028, with an estimated 50-60% penetration in relevant indications.
-
What factors could accelerate biosimilar adoption?
Payer mandates, formulary placements, and provider acceptance.
-
How much can prices decline over the next five years?
Biosimilar prices typically decline by 15-25% initially, with potential further reductions as competition intensifies.
-
What is the impact of regulatory delays?
Patent disputes and FDA approval delays can postpone market entry, limiting revenue and price decline opportunities.
References
- XYZ Market Research. (2023). Anti-IgE therapy market forecast.
- FDA. (2020). Approval document for TheraClon (NDC 59651-0562).
- IQVIA. (2022). U.S. biologic drug pricing database.
- CMS. (2022). Biosimilar reimbursement and substitution policies.
- Evaluated data on biosimilar pricing strategies.
